ALFA FinderNSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,590.00
- Market cap
- ₹73,096 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 50.4×Sector 43.0×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Like-for-like growth ~20% and ex-IGI EBITDA margin 21%, yet H1 operating cash was negative; H2 cash recovery is the test.
Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Other employee stock options announcements
All →SIS Employee Stock Options
SIS Limited allotted 2,683 equity shares to employees on exercise of ESOP options. Paid-up capital rose to Rs.69.43 Crore; no issue price is disclosed.
FSN E-Commerce Ventures Employee Stock Options
FSN E-Commerce allotted 6,61,020 equity shares to employees on exercise of vested ESOPs. Issued and paid-up capital increases; no transaction price is disclosed.
One Point One Solutions Employee Stock Options
One Point One Solutions allotted 1,45,754 equity shares to employees under its ESOS 2022 at an exercise price of ₹18.85. Paid-up capital rose to ₹52.62 crore.
Au Small Finance Bank Employee Stock Options
AU Small Finance Bank allotted 1,86,955 shares on exercised ESOPs under four schemes. Paid-up capital rises accordingly, with no event value disclosed.
Hero Motors Employee Stock Options
Hero Motors allotted 64,69,399 equity shares to employees exercising ESOP-2022 options at Rs. 69.14 each. The allotment lifts paid-up capital to 46,06,84,975 shares.
PB Fintech Employee Stock Options
PB Fintech allotted 24,06,644 equity shares to employees under ESOP 2021 on 7 November 2026. Issued capital rises to Rs 93.03 Crore; shares total 46.52 crore.